Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura
Open Access
- 19 April 2012
- journal article
- Published by American Society of Hematology in Blood
- Vol. 119 (16), 3836-3843
- https://doi.org/10.1182/blood-2011-12-399501
Abstract
Thrombotic thrombocytopenic purpura (TTP) is primarily caused by immunoglobulin G (IgG) autoantibodies against A Disintegrin And Metalloprotease with ThromboSpondin type 1 repeats, 13 (ADAMTS13). Nearly all adult idiopathic TTP patients harbor IgGs, which bind the spacer domain of ADAMTS13, a region critical for recognition and proteolysis of von Willebrand factor (VWF). We hypothesize that a modification of an exosite in the spacer domain may generate ADAMTS13 variants with reduced autoantibody binding while preserving or enhancing specific activity. Site-directed mutagenesis was used to generate a series of ADAMTS13 variants, and their functional properties were assessed. Of 24 novel ADAMTS13 variants, 2 (ie, M4, R660K/F592Y/R568K/Y661F and M5, R660K/F592Y/R568K/Y661F/Y665F) exhibited increased specific activity approximately 4- to 5-fold and approximately 10- to 12-fold cleaving a peptide VWF73 substrate and multimeric VWF, respectively. More interestingly, the gain-of-function ADAMTS13 variants were more resistant to inhibition by anti-ADAMTS13 autoantibodies from patients with acquired idiopathic TTP because of reduced binding by anti-ADAMTS13 IgGs. These results shed more light on the critical role of the exosite in the spacer domain in substrate recognition. Our findings also help understand the pathogenesis of acquired autoimmune TTP. The autoantibody-resistant ADAMTS13 variants may be further developed as a novel therapeutic for acquired TTP with inhibitors.Keywords
This publication has 39 references indexed in Scilit:
- Essential Domains of A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13 Metalloprotease Required for Modulation of Arterial ThrombosisArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWFBlood, 2010
- Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factorProceedings of the National Academy of Sciences of the United States of America, 2009
- Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage siteBlood, 2009
- Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factorProceedings of the National Academy of Sciences of the United States of America, 2009
- The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formationBlood, 2009
- Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13Proceedings of the National Academy of Sciences of the United States of America, 2008
- Pathogenesis of Thrombotic MicroangiopathiesAnnual Review Of Pathology-Mechanisms Of Disease, 2008
- Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloproteaseProceedings of the National Academy of Sciences of the United States of America, 2006
- Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivoJournal of Thrombosis and Haemostasis, 2006